How Mutant p53 Hijacks VWF Expression in Tumor Cells – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Noorossadat Seyyedi et al., adding:
”The role of mutant p53R175H in de novo activation of von Willebrand factor expression in tumor cells
Von Willebrand factor is normally made only by endothelial cells and megakaryocytes, yet some cancers switch it on.
Across 100 VWF-positive cancer lines, this study tied that aberrant expression to the mutant p53R175H, which engages the repressor NF-IB and activator GATA6 to drive VWF from the promoter.
The resulting VWF fueled cancer cell to platelet aggregates, and plakoglobin reversed the effect.”
Title: The role of mutant p53R175H in de novo activation of von Willebrand factor expression in tumor cells
Authors: Noorossadat Seyyedi, Chu Shiun Lo, Parnian Alavi, Manijeh Pasdar, Nadia Jahroudi
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 18, 2026, 12:58Pierpaolo Di Micco: DOACs vs Vitamin K Antagonists in Long-Term Anticoagulation
-
Oct 18, 2026, 12:51Arianne Missimer: Understanding Ferritin Levels Beyond the Normal Range
-
Oct 18, 2026, 12:37Roberto C. Iglesias: Colon Cancer Prevention Beyond Supplements and Vitamins
-
Oct 18, 2026, 12:27Rafael Alejandro Camero Del Vecchio: Paroxysmal Nocturnal Hemoglobinuria Advancing Complement Inhibition with Ravulizumab
-
Oct 18, 2026, 12:26Abdul Mannan: When INR Misleads – Rethinking Bleeding Risk in Cirrhosis
-
Oct 18, 2026, 12:14Stéphane Laurent: The People and Technology Behind Safe Blood Transfusion
-
Oct 18, 2026, 12:14Abhi Kapuria: When VTE Prophylaxis Breaks Down in the ICU
-
Oct 18, 2026, 11:37Lee Anne Sorto: Beyond Compliance – Making Audits Count in Transfusion Safety
-
Oct 18, 2026, 11:26Valentina Ajello: Does ANH Benefit Women in Cardiac Surgery?